pamidronate has been researched along with Metastase in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy." | 9.09 | Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999) |
| " generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i." | 7.73 | Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks." | 7.73 | Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005) |
| " This model was applied to the placebo-control arm of a pamidronate study in patients with malignant bone disease from breast cancer." | 5.14 | Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, PP; Smith, MR; Terpos, E, 2009) |
| "To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy." | 5.09 | Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999) |
| "Zoledronic acid seems to be the most efficacious bisphosphonate for reducing the risk of SREs in patients with cancer of the breast or prostate and those with multiple myeloma." | 4.89 | Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. ( Brown, J; Fullarton, JR; Palmieri, C, 2013) |
| " generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i." | 3.73 | Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks." | 3.73 | Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005) |
| " In conclusion, RT combined with BMA was found to be more effective than BMA alone for the treatment of osteolytic bone metastasis, which thereby improves the prognosis." | 1.56 | Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. ( Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H, 2020) |
| "For patients with HCM who do not achieve a response from bisphosphonates, or for those who need repeated dosing more often than expected, changing to a different drug class could be an alternative." | 1.35 | A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm. ( Linneman, T; McMahan, J, 2009) |
| "The various features of carcinoid tumors metastasizing to the skeleton are briefly reviewed." | 1.31 | Case of an ivory vertebra. ( Ball, DW; Basaria, S; Belzberg, AJ; McCarthy, EF, 2000) |
| " No significant increase in the median survival time of tumor-bearing animals was achieved at the two dosage schemes tested, i." | 1.27 | Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma. ( Schmähl, D; Wingen, F, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, H | 1 |
| Makita, C | 1 |
| Manabe, Y | 1 |
| Kajima, M | 1 |
| Matsuyama, K | 1 |
| Matsuo, M | 1 |
| Hahn, NM | 1 |
| Yiannoutsos, CT | 1 |
| Kirkpatrick, K | 1 |
| Sharma, J | 1 |
| Sweeney, CJ | 1 |
| Palmieri, C | 1 |
| Fullarton, JR | 1 |
| Brown, J | 1 |
| Addison, CL | 1 |
| Bouganim, N | 1 |
| Hilton, J | 1 |
| Vandermeer, L | 1 |
| Dent, S | 1 |
| Amir, E | 1 |
| Hopkins, S | 1 |
| Kuchuk, I | 1 |
| Segal, R | 1 |
| Song, X | 1 |
| Gertler, S | 1 |
| Mazzarello, S | 1 |
| Dranitsaris, G | 1 |
| Ooi, D | 1 |
| Pond, G | 1 |
| Clemons, M | 1 |
| McMahan, J | 1 |
| Linneman, T | 1 |
| Major, PP | 1 |
| Cook, RJ | 1 |
| Lipton, A | 2 |
| Smith, MR | 1 |
| Terpos, E | 1 |
| Coleman, RE | 1 |
| Ngamphaiboon, N | 1 |
| Frustino, JL | 1 |
| Kossoff, EB | 1 |
| Sullivan, MA | 1 |
| O'Connor, TL | 1 |
| El-Abdaimi, K | 1 |
| Ste-Marie, LG | 1 |
| Papavasiliou, V | 1 |
| Dion, N | 1 |
| Cardinal, PE | 1 |
| Huang, D | 1 |
| Kremer, R | 1 |
| Wenzel, C | 1 |
| Bartsch, R | 1 |
| Hussian, D | 1 |
| Pluschnig, U | 1 |
| Locker, GJ | 1 |
| Sevelda, U | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| De Cock, E | 1 |
| Hutton, J | 1 |
| Canney, P | 1 |
| Body, JJ | 1 |
| Barrett-Lee, P | 1 |
| Neary, MP | 1 |
| Lewis, G | 1 |
| Liauw, W | 1 |
| Segelov, E | 1 |
| Lih, A | 1 |
| Dunleavy, R | 1 |
| Links, M | 1 |
| Ward, R | 1 |
| Cremers, SC | 1 |
| Papapoulos, SE | 1 |
| Gelderblom, H | 1 |
| Seynaeve, C | 1 |
| den Hartigh, J | 1 |
| Vermeij, P | 1 |
| van der Rijt, CC | 1 |
| van Zuylen, L | 1 |
| Sauter, M | 1 |
| Jülg, B | 1 |
| Porubsky, S | 1 |
| Cohen, C | 1 |
| Fischereder, M | 1 |
| Sitter, T | 1 |
| Schlondorff, D | 1 |
| Gröne, HJ | 1 |
| Boissier, S | 1 |
| Magnetto, S | 1 |
| Frappart, L | 1 |
| Cuzin, B | 1 |
| Ebetino, FH | 1 |
| Delmas, PD | 1 |
| Clezardin, P | 1 |
| Theriault, RL | 1 |
| Hortobagyi, GN | 1 |
| Leff, R | 1 |
| Glück, S | 1 |
| Stewart, JF | 1 |
| Costello, S | 1 |
| Kennedy, I | 1 |
| Simeone, J | 1 |
| Seaman, JJ | 1 |
| Knight, RD | 1 |
| Mellars, K | 1 |
| Heffernan, M | 1 |
| Reitsma, DJ | 1 |
| Basaria, S | 1 |
| McCarthy, EF | 1 |
| Belzberg, AJ | 1 |
| Ball, DW | 1 |
| Johnston, SR | 1 |
| Korfel, A | 1 |
| Fischer, L | 1 |
| Foss, HD | 1 |
| Koch, HC | 1 |
| Thiel, E | 1 |
| Clarke, NW | 1 |
| Holbrook, IB | 1 |
| McClure, J | 1 |
| George, NJ | 1 |
| Wingen, F | 1 |
| Schmähl, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060] | Phase 3 | 63 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to Terminated due to low accrual) | ||
| Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone[NCT00760370] | Phase 2 | 60 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Risedronate Arm | 11 |
| Placebo Arm | 13 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate Arm | 50 |
| Placebo Arm | 29 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate | 72.5 |
| Placebo | 71.5 |
"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks
| Intervention | nmol/mmol creatinine (Median) | |
|---|---|---|
| week 24 | baseline | |
| Placebo Arm | 12.62 | 10.12 |
| Risedronate Arm | 6.91 | 8.83 |
Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week
| Intervention | ng/mL (Median) | |
|---|---|---|
| 24 week | baseline | |
| Placebo Arm | 13.16 | 19.50 |
| Risedronate Arm | 9.5 | 20.95 |
Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week
| Intervention | ug/L (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 27.35 | 18.24 |
| Risedronate Arm | 11.88 | 20.08 |
"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week
| Intervention | nmol BCE/mmol creatinine (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 62.95 | 48.08 |
| Risedronate Arm | 20.63 | 41.33 |
2 reviews available for pamidronate and Metastase
| Article | Year |
|---|---|
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; | 2013 |
Systemic treatment of metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inh | 2001 |
5 trials available for pamidronate and Metastase
| Article | Year |
|---|---|
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bi | 2014 |
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
Topics: Administration, Intravenous; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Ne | 2014 |
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; H | 2009 |
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Disea | 1999 |
Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone and Bones; Diphosphonates; Humans; Hydroxyproline; | 1991 |
13 other studies available for pamidronate and Metastase
| Article | Year |
|---|---|
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosum | 2020 |
A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
Topics: Aged; Algorithms; Bone Density Conservation Agents; Calcitonin; Carcinoma, Transitional Cell; Crysta | 2009 |
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anti | 2011 |
Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Calcium; Cell Line, Tumor; Creatinin | 2003 |
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; I | 2004 |
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort | 2005 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dis | 2005 |
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone R | 2005 |
Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
Topics: Antineoplastic Agents; Biopsy; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosph | 2006 |
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhes | 1997 |
Case of an ivory vertebra.
Topics: Alendronate; Alkaline Phosphatase; Biopsy; Bone Marrow; Carcinoid Tumor; Diagnosis, Differential; Di | 2000 |
Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cell Differentiation; Cisp | 2001 |
Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma.
Topics: Animals; Autoradiography; Bone Neoplasms; Diphosphonates; Electrolytes; Male; Neoplasm Metastasis; N | 1985 |